Drug Interaction Report

GENERALLY AVOID: Coadministration with moderate to potent inhibitors of CYP450 2C8 may increase the plasma concentrations and effects of tovorafenib, which has been found in vitro to be primarily metabolized by CYP450 2C8 and aldehyde oxidase, and to a lesser extent, by the isoenzymes CYP450 3A, 2C9, and 2C19. Increased plasma concentrations may increase the risk for adverse drug reactions including but not limited to, hemorrhage, skin toxicity, photosensitivity, hepatotoxicity, and reduced growth velocity in patients 18 years of age or younger. However, data from formal clinical drug interaction studies are not available.

MANAGEMENT: According to the manufacturer, concomitant use of tovorafenib with moderate to potent inhibitors of CYP450 2C8 should generally be avoided.

ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.

MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.